Alzheimer's agitation

Otsuka Drug Candidate Fails Phase III Alzheimer’s Agitation Study
BioSpace
Tue, 02/13/24 - 11:27 am
Otsuka
clinical trials
AVP-786
Alzheimer's agitation
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
Mon, 08/14/23 - 11:23 am
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
BioXCell’s potential episodic Alzheimer’s agitation treatment marred by missed trial protocols, fabricated emails and failed endpoint
Fierce Pharma
Thu, 06/29/23 - 11:42 am
BioXCell
Alzheimer's disease
Alzheimer's agitation
dexmedetomidine
SEC
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Yahoo/Benzinga
Thu, 05/11/23 - 08:53 pm
Otsuka
Lundbeck
FDA
Rexulti
Alzheimer's agitation
IGC starts clinical trial of drug candidate to treat agitation in dementia
Clinical Trials Arena
Fri, 12/2/22 - 11:00 am
IGC
clinical trials
IGC-AD1
Alzheimer's agitation
Alzheimer's disease
Axsome Headed to FDA after Phase III Alzheimer's Agitation Win
BioSpace
Mon, 11/28/22 - 10:23 am
Axsome Therapeutics
clinical trials
Alzheimer's disease
Alzheimer's agitation
AXS-05
BioXcel scores another win with reformulated Pfizer sedative, this time in an Alzheimer's symptom
Endpoints
Tue, 01/5/21 - 10:48 pm
BioXcel
clinical trials
artificial intelligence
agitation
Alzheimer's agitation
Avanir's AVP-786 meets in Phase III for Alzheimer's agitation
BioCentury
Mon, 03/25/19 - 10:28 pm
Avanir Pharmaceuticals
AVP-786
Alzheimer's disease
Alzheimer's agitation